Welcome to Essity's Business Area Web Presentations

DAY 1 – ESSITY GROUP and HEALTH & MEDICAL



December 7, 2022 at 15:00– 16:15 CET DAY 2 – PROFESSIONAL HYGIENE



December 8, 2022 at 15:00- 16:00 CET DAY 3 – CONSUMER GOODS



December 9, 2022 at 15:00- 16:00 CET



Business Area Web Presentation - Essity Group

December 7, 2022 1

Health & Medical

TENA

TENA

overamor

ctim

Health & Medical

SEK 21.7bn Share of Group Net Sales 2021 18% SEK 3.8bn Share of Group Adjusted EBITA¹⁾ 2021 26%









Actimove[®]



Cutimed[®] Hydrofera[®]

Delta-Cast[®]

¹⁾ Excluding items affecting comparability



Business Area Web Presentation - Health & Medical

December 7, 2022 3

Net Sales Split 2021 – Categories



December 7, 2022

4

Net Sales Split 2021 – Geographies



essity Business Area Web Presentation - Health & Medical

eee

December 7, 2022 5

Key Figures 9M 2022

+10.8%

Net sales growth¹⁾

37.3%

Adjusted gross margin²⁾

11.8%

Adjusted EBITA margin²⁾

Adjusted

ROCE²⁾

9.5%

Including organic sales growth and acquisitions
Excluding items affecting comparability



Business Area Web Presentation - Health & Medical



Current Environment

essity

Why Price Increases Take Longer in Incontinence Products Health Care



Long-term contracts (majority 3 years)

Health & Medical Categories



👹 essity 🛛

Business Area Web Presentation - Health & Medical

December 7, 2022 9

Health & Medical Products and Brands



B essity



Source: Irwin et all, Worldwide prevalence estimates of lower urinary tract symptoms, overactive balder, urinary incontinence and bladder outlet obstruction, 2010



Compression Therapy for Lymphatic and Venous Conditions

>150M

people suffer from LYMPHEDEMA of adult population¹⁾ affected by CHRONIC VENOUS INSUFFICENCY

>5%

Treating Chronic and Surgical Wounds, Cuts and Scratches

1.6% of population have CHRONIC WOUNDS

BILLIONS

suffer from INJURIES AND WOUNDS

High Prevalence for Orthopedic Injuries and Chronic Conditions

Hundreds of Millions orthopedic injuries

per year, globally

10%

of population +60 years suffer from OSTEOARTHRITIS

Current Addressable Market Health & Medical





Source: The information has been compiled by Essity for presentation purposes based on data taken from external market sources including but not limited to retail audit companies, Price Hanna Consultants, SmartTRAK, Fastmarkets RISI and national macroeconomic data.



Business Area Web Presentation - Health & Medical



Global Market Positions



Source: The information has been compiled by Essity for presentation purposes based on data taken from external market sources including but not limited to retail audit companies, Price Hanna Consultants, SmartTRAK, Fastmarkets RISI and national macroeconomic data.



Business Area Web Presentation - Health & Medical

Unique Set of Capabilities Combining Consumer and Medical Expertise

- Strong R&D capabilities
- Customer insights all stakeholders
- Broad channel presence
- Medical expertise
- Benchmark in Brand building
- Consumer/Shopper know-how











Leukoplast®





















Wound Care Take the Lead, Leveraging our unique solutions





Wound Care – Upward Moving #5



■ Expected Market Growth CAGR (Compound Annual Growth Rate) 2023-2027

Source: The information has been compiled by Essity for presentation purposes based on data taken from external market sources including but not limited to retail audit companies, Price Hanna Consultants, SmartTRAK, Fastmarkets RISI and national macroeconomic data.

eee essity Business Area Web Presentation - Health & Medical

Innovations Leukomed T plus **Skin Sensitive** Leukoplast Eco





Wound Care



Organic Sales Growth 9M 2022

essity

Compression Therapy - Essity Global #1

Other

Market Size 2021: EUR ~1.5BN 7 2-3%

Juzo

Essity, 13%

Sigvaris

Medi

Source: The information has been compiled by Essity for presentation purposes based on data taken from external market sources including but not limited to retail audit companies, Price Hanna Consultants, SmartTRAK, Fastmarkets RISI and national macroeconomic data.

Business Area Web Presentation - Health & Medical

Compression Therapy Strengthen our #1 Position





Delighting All Stakeholders

Convenience for **the customer**



Business Area Web Presentation - Health & Medical

Health Economic benefits for **the payer**



Superior comfort & style for **the user**



December 7, 2022 26

Innovation JOBST





Business Area Web Presentation - Health & Medical

Orthopedics – Fragmented Market with Many Growth Opportunities

DJO Global

3M

Other

Market Size 2021: EUR ~3.5BN 7 ~4%

Essity, 6%

Breg & Bledsoe

Source: The information has been compiled by Essity for presentation purposes based on data taken from external market sources including but not limited to retail audit companies, Price Hanna Consultants, SmartTRAK, Fastmarkets RISI and national macroeconomic data.



Business Area Web Presentation - Health & Medical

Orthopedics Strengthen position, building on market leadership in Fracture Management

essity

Delta-Cast[®] Actimove[®]

Orthopedics

+8%

Organic Sales Growth 9M 2022

+37%

Organic Sales Growth Physiotherapy

essity

Incontinence Products Lead & Shape the Market

pocstin





TENA Global #1 Incontinence Products Health Care

Other

Market Size 2021: EUR~5BN 7~4%

Hartmann

Essity, 22%

Medline

Ontex

Expected Market Growth CAGR (Compound Annual Growth Rate) 2023-2027

Source: The information has been compiled by Essity for presentation purposes based on data taken from external market sources including but not limited to retail audit companies, Price Hanna macroeconomic data

sessity Business Area Web Presentation - Health & Medical



Source: The information has been compiled by Essity for presentation purposes based on data taken from external market sources including but not limited to retail audit companies, Price Hanna Consultants, SmartTRAK, Fastmarkets RISI and national macroeconomic data.

eee essity Business Area Web Presentation - Health & Medical

TENA Europe #1 Incontinence Products Health Care



■ Expected Market Growth CAGR (Compound Annual Growth Rate) 2023-2027

Source: The information has been compiled by Essity for presentation purposes based on data taken from external market sources including but not limited to retail audit companies, Price Hanna Consultants, SmartTRAK, Fastmarkets RISI and national macroeconomic data.

eee essity Business Area Web Presentation - Health & Medical

Innovation TENA Proskin Flex



Business Area Web Presentation - Health & Medical

Best Individual Care & Best Use of Available Resources



Business Area Web Presentation - Health & Medical

December 7, 2022 36

Enabling Cost Efficient Quality Care



Value based procurement pilot

essity

Business Area Web Presentation - Health & Medical

Expansion Strategy for Profitable Growth

CHANNELS/CUSTOMERS

GEOGRAPHIES

OFFERS



- Home Care
- Care Giving relatives
- Selfpay

- Emerging markets
- Penetration globally



- Sustainable solutions
- Continuum of care
- Digital solutions

Expanding Offering Along Continuum

of Care		Wellness	Prevention	Assessment	Management	Care Remote Delivery monitoring
; ::	Acute Wounds					
ليسط	Trauma & Injury					
$\overline{\mathbf{r}}$	Incontinence					
Cir)	Chronic Wounds		•			
→J](←	Venous & Lymphatic Conditions	4				
F	Chronic Orthopedic Conditions					



TENA SmartCare

Up to

28%

Waste

Reduction

Up to

29%

Less

Leakages

Up to





Enhancing customer experience and improving sales & marketing productivity via omnichannel

و a



Priorities

- Continue price increases and efficiency improvements
- Innovate for differentiation, cost position improvements and sustainability
- Enhance customer experience
- Accelerate growth in highest margin areas





Forward-looking Statements

Certain statements in this presentation includes forward-looking statements, including statements reflecting management's current views relating to the growth of the market, future market conditions, future events, financial conditions, and expected operational performance, including, in particular the following: -Our goals, strategies and operational expectations; -Industry trends, future characteristics and development of the markets in which we operate; -Our future liquidity, capital resources, capital expenditures and cost savings; -The expected demand for new products and services as well as plans to launch new products and services including R&D expenditures; -The ability to deliver on future plans and to realize potential for future growth; -The expected performance of strategic cooperation activities and joint ventures; -The time until acquired entities and businesses will be integrated and accretive to income; and -Technology and industry trends including the regulatory and standardization environment in which we operate, competition and customer structure.

We caution investors that these statements are subject to risks and uncertainties many of which are difficult to predict and generally beyond our control that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial risks, including foreign currency fluctuations, currency exchange or pricing controls and localized volatility; (2) the ability to successfully manage local, regional or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to affect the expected dividend payacturing plant ability to manage disruptions in credit markets or changes to our credit rating; (4) the ability to maintain key manufacturing and supply arrangements (including execution of supply chain optimizations, and sole supplier and sole many to affect the expected dividend payacturing plant arrangements) and to manage disruption of business due to factors outside of our control, such as, natural disasters and acts of war or terrorism; (5) the ability to successfully manage cost fluctuations and pressures, including prices of commodity and raw materials, and costs of labor, transportation, energy, pension and healthcare; (6) the ability to stay on the leading edge of innovation, obtain necessary intellectual property protections and successfully managing real to competitive factors such as prices, promotional incentives and trade terms for products; (7) the ability to manage and maintain key customer relationships; (9) the ability to protect our reputation and brand equity by successfully managing real or perceive issues, including power suppliers, distributors, contractors and external business partners; (11) the ability to rely on and maintain key company and third party information technology systems, networks and services, and market contraction; (13) the ability to successfully manage trequerements and matter synthes and technologing and matters within during pay and printer support, competition and practers such as our suppliers; distributors, contractors and external business partners; (11) the ability to

Important factors that could affect whether and to what extent any of our forward-looking statements materialize include, but are not limited to, the factors described above and in the section Risk factors in the most recent Annual and Sustainability Report and in our quarterly reports. These forward-looking statements also represent our estimates and assumptions only as of the date that they were made and are not to be seen as projections or earnings guidance. We expressly disclaim a duty to provide updates to these forward-looking statements, and the estimates and assumptions associated with them, after the date of this presentation, to reflect events or changes in circumstances or changes in expectations or the occurrence of anticipated events, whether as a result of new information, future events or otherwise.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any of our securities.



Investor Relations Contacts

Janet Öst Johan Karl Sandra Åben son 5.81 rgren +46 70 564 96 85 +46 0 +46 70 511 sandra.aberg johan.ir.karl on@e ity.com ianet.os

